NeoGenomics, Inc. is a high-complexity CLIA-certified clinical laboratory and pharma services company that specializes in cancer genetics diagnostic testing, the fastest growing segment of the laboratory industry. The company's testing services include cytogenetics, fluorescence in-situ hybridization (FISH), flow cytometry, immunohistochemistry, anatomic pathology, and molecular genetics. Headquartered in Fort Myers, FL, NeoGenomics maintains a network of testing facilities across the US. NeoGenomics services the needs of pathologists, oncologists, urologists and other physician specialists, academic institutions, and the pharmaceutical industry.
The company’s acquisition of Clarient at the end of 2015 significantly transformed the company in terms of reach and capabilities. It more than doubled the size of the company overnight and puts the company on a strong path to achieve its vision of becoming the world’s leading cancer testing and information company.
The company has aggressively accelerated its pace of innovation adding new cancer tests. The company’s targeted tumor-specific multimodality NeoTYPE profiles, which combine molecular, FISH and IHC testing, are gaining acceptance by pathologists and clinicians. The new Liquid Biopsy NeoLAB family of tests now includes 16 different liquid biopsy test. Clarient’s expertise in PDL1 testing has further broadened the company’s cancer testing menu.
This presentation provides an overview of NeoGenomics' proposed acquisition of Clarient, which would more than double NeoGenomics' revenue. The strategic rationale is that the combined company would have greater scale and a more balanced oncology product portfolio, allowing it to be a lower-cost provider. It would also gain a larger clinical trials business and enhanced geographic coverage. Synergies of $20-30 million annually are projected from consolidating laboratories, purchasing, cross-selling and other areas. The acquisition supports NeoGenomics' strategy of using M&A to accelerate its vision of becoming a leading cancer testing and information company.
NeoGenomics Company Overview 2014-09-12 includes the following sections:
-Forward-looking Statements
-Investment Highlights
-Experienced Management Team
-Company Overview
-Proven Track Record Of Consistent Growth
-U.S. Cancer Testing Market Size $10-12 Billion
-NeoGenomics' Cancer Testing Services
-Customer Targets
-Accelerating Pace of Innovation
-90+ New Assays Launched Since January 2012
-A Growing Commercial & Facility Footprint
-Acquisition of Path Logic
-Strategic Alliance
-2014 and 2015 Strategic Priorities
-Accelerating Cash Flow & Earnings
-Adjusted EBITDA Metrics
- And much more...
This presentation provides an overview of the company and its acquisition of Clarient. It summarizes that the acquisition will more than double the company's revenue and more than triple its adjusted EBITDA. The acquisition provides key benefits like synergies of $20-30 million annually within 3-5 years, a combined leadership in cancer testing, and expanded geographic coverage across the United States with field sales representatives.
- NeoGenomics is acquiring Clarient, which should more than double NeoGenomics' revenue in 2016.
- The acquisition creates a leading cancer testing and information company with expanded geographic coverage and a more comprehensive product menu.
- Synergies of $20-30 million per year are expected from cost savings and cross-selling opportunities between the two companies.
This company presentation provides an overview of a cancer genetic testing services company. Key points include:
- The company has experienced strong and consistent growth in revenue and test volume over the past 10 years through both organic growth and acquisitions.
- It provides a broad menu of genetic and molecular testing services including next generation sequencing and is developing liquid biopsy tests.
- The company has an experienced management team with experience in large reference laboratories. It is focused on innovation, cost management, and expanding its commercial footprint.
- Financial results show increasing margins, productivity, and adjusted EBITDA despite lower average prices per test, demonstrating strong operating leverage as the business scales.
Specialized oncology reference laboratory providing the latest testing technologies, global/tech-only options, and interactive education to the pathology community
Offer the complete spectrum of diagnostic services through nationwide network of laboratories
Dedicated to providing superior service, faster turn-around times, and complete attention to the needs of our clients and their patients
This presentation provides an overview of the company and its recent acquisition of Clarient. It summarizes that the acquisition is expected to more than double the company's revenue and more than triple its adjusted EBITDA in 2016. The company provides cancer genetic testing services and sees significant opportunity for growth and consolidation in the dynamic and expanding industry. The acquisition combines the companies' complementary assets and is expected to generate $20-30 million in annual synergies within 3-5 years.
This presentation provides an overview of the company and its recent acquisition of Clarient. It summarizes that the acquisition is expected to more than double the company's revenue and more than triple its adjusted EBITDA in 2016. The company operates a fast-growing cancer genetics laboratory and sees significant opportunity in consolidating the dynamic and consolidating industry. The acquisition combines the companies' complementary assets and geographic footprints to create a leader in hematological and solid tumor cancer testing with synergies of $20-30 million annually.
This presentation provides an overview of NeoGenomics' proposed acquisition of Clarient, which would more than double NeoGenomics' revenue. The strategic rationale is that the combined company would have greater scale and a more balanced oncology product portfolio, allowing it to be a lower-cost provider. It would also gain a larger clinical trials business and enhanced geographic coverage. Synergies of $20-30 million annually are projected from consolidating laboratories, purchasing, cross-selling and other areas. The acquisition supports NeoGenomics' strategy of using M&A to accelerate its vision of becoming a leading cancer testing and information company.
NeoGenomics Company Overview 2014-09-12 includes the following sections:
-Forward-looking Statements
-Investment Highlights
-Experienced Management Team
-Company Overview
-Proven Track Record Of Consistent Growth
-U.S. Cancer Testing Market Size $10-12 Billion
-NeoGenomics' Cancer Testing Services
-Customer Targets
-Accelerating Pace of Innovation
-90+ New Assays Launched Since January 2012
-A Growing Commercial & Facility Footprint
-Acquisition of Path Logic
-Strategic Alliance
-2014 and 2015 Strategic Priorities
-Accelerating Cash Flow & Earnings
-Adjusted EBITDA Metrics
- And much more...
This presentation provides an overview of the company and its acquisition of Clarient. It summarizes that the acquisition will more than double the company's revenue and more than triple its adjusted EBITDA. The acquisition provides key benefits like synergies of $20-30 million annually within 3-5 years, a combined leadership in cancer testing, and expanded geographic coverage across the United States with field sales representatives.
- NeoGenomics is acquiring Clarient, which should more than double NeoGenomics' revenue in 2016.
- The acquisition creates a leading cancer testing and information company with expanded geographic coverage and a more comprehensive product menu.
- Synergies of $20-30 million per year are expected from cost savings and cross-selling opportunities between the two companies.
This company presentation provides an overview of a cancer genetic testing services company. Key points include:
- The company has experienced strong and consistent growth in revenue and test volume over the past 10 years through both organic growth and acquisitions.
- It provides a broad menu of genetic and molecular testing services including next generation sequencing and is developing liquid biopsy tests.
- The company has an experienced management team with experience in large reference laboratories. It is focused on innovation, cost management, and expanding its commercial footprint.
- Financial results show increasing margins, productivity, and adjusted EBITDA despite lower average prices per test, demonstrating strong operating leverage as the business scales.
Specialized oncology reference laboratory providing the latest testing technologies, global/tech-only options, and interactive education to the pathology community
Offer the complete spectrum of diagnostic services through nationwide network of laboratories
Dedicated to providing superior service, faster turn-around times, and complete attention to the needs of our clients and their patients
This presentation provides an overview of the company and its recent acquisition of Clarient. It summarizes that the acquisition is expected to more than double the company's revenue and more than triple its adjusted EBITDA in 2016. The company provides cancer genetic testing services and sees significant opportunity for growth and consolidation in the dynamic and expanding industry. The acquisition combines the companies' complementary assets and is expected to generate $20-30 million in annual synergies within 3-5 years.
This presentation provides an overview of the company and its recent acquisition of Clarient. It summarizes that the acquisition is expected to more than double the company's revenue and more than triple its adjusted EBITDA in 2016. The company operates a fast-growing cancer genetics laboratory and sees significant opportunity in consolidating the dynamic and consolidating industry. The acquisition combines the companies' complementary assets and geographic footprints to create a leader in hematological and solid tumor cancer testing with synergies of $20-30 million annually.
- The company provides an overview presentation of its business operations as a fast growing cancer genetics laboratory.
- Key highlights include strategic client partnerships through its "tech-only" model, an industry-leading growth rate in revenue and test volume, and the most comprehensive cancer testing menu in the industry.
- The acquisition of Clarient is expected to more than double the company's revenue and more than triple adjusted EBITDA for 2016.
- The company provides an overview presentation of its business operations, growth strategy, and recent acquisition of Clarient, which is expected to more than double its revenue and more than triple its adjusted EBITDA in 2016.
- Key highlights include its focus on being a leading cancer genetics testing provider, experience in consolidating the industry, a comprehensive testing menu, and strategic partnerships with pathologists and oncologists.
- Financial projections estimate the combined company will generate around $247 million in revenue and $35-40 million in adjusted EBITDA in 2016 following the acquisition.
- The company provides an overview presentation of its business operations, growth strategy, and recent acquisition of Clarient, which is expected to more than double its revenue and more than triple its adjusted EBITDA in 2016.
- Key highlights include its focus on cancer genetics testing, strategic partnerships with pathologists and oncologists, a comprehensive testing menu, and experienced management team.
- Financial projections estimate combined pro forma revenue of $242-252 million and adjusted EBITDA of $35-40 million in 2016 following the acquisition of Clarient. Synergies from the acquisition are expected to provide $20-30 million in annual cost savings.
This presentation provides an overview of a cancer genetics laboratory company. Key points include:
- The company has experienced strong and consistent revenue and test volume growth through strategic partnerships and an expanding test menu. An upcoming acquisition is expected to more than double revenue and more than triple adjusted EBITDA.
- The management team has extensive experience in large cap clinical laboratories.
- The company addresses a $5 billion clinical cancer testing market and has opportunities for further growth through innovation, such as liquid biopsy tests and partnerships with oncologists.
- Recent acquisitions and an expanding test menu have contributed to accelerating same store sales growth.
- NeoGenomics is a pure-play cancer genetics testing company that has experienced fast revenue and test volume growth through expanding its test menu and increasing sales force productivity. Its "tech-only" business model focuses on partnerships with oncologists and hospitals to provide genetic testing services.
- The company has consistently grown its annual revenue and tests performed historically through new test innovations, a growing sales force, and greater productivity. It is targeting further market share gains and operating leverage to accelerate cash flow and earnings growth.
NeoGenomics provides cancer genetic testing services to oncologists, pathologists, and hospitals. It has experienced strong and consistent growth in revenue and tests performed annually through expanding its test menu, increasing sales force productivity, and gaining market share. The company aims to continue its growth by launching new tests, pursuing partnerships and acquisitions, and capitalizing on the large and growing market for cancer genetic testing fueled by an aging population and advancements in targeted therapies.
This presentation provides an overview of NeoGenomics, a cancer genetics testing company. Key points include:
- NeoGenomics has experienced strong and consistent growth in revenue and test volume historically through strategic partnerships and an expanding test menu.
- The company focuses on fast turnaround times and exceptional client service to drive continued growth.
- Management aims to increase market share and profitability through expanding sales coverage, new test offerings like next generation sequencing, and potential M&A opportunities.
- NeoGenomics seeks to capitalize on favorable industry trends like an aging population, rise of personalized medicine, and consolidation in the cancer diagnostics field.
The presentation provides an overview of NeoGenomics, a cancer genetic testing company. It highlights the company's consistent historical growth in tests performed and revenue. The management team has significant experience in large cap clinical laboratories. The company aims to continue expanding its test menu and market share through new product development and partnerships within the fast-growing cancer genetic testing industry.
In this NeoGenomics Laboratory Company Overview Presentation 02/19/2014, you will find detail information on the following highlights:
•Fast growing cancer genetics lab servicing Oncologists, Pathologists and Hospitals
•Strategic client partnerships created by “Tech-Only” model
•Dynamic, rapidly-growing and consolidating industry
•Industry-leading revenue & test volume growth
•Strong productivity and operating leverage leading to accelerating cash flow and net income
•Strong Management Team with large cap lab experience
Liquid biopsy from a simple blood test enabling personalised cancer care | Sh...ANGLE plc
Liquid biopsy from a simple blood test is enabling personalised cancer care. The Parsortix system from ANGLE can harvest cancer cells from blood (liquid biopsy) in a non-invasive and repeatable way. This provides a new approach to obtaining cancer cells for analysis compared to traditional tumour biopsies. Key opinion leaders have evaluated the Parsortix system and found that it captures all types of cancer cells with high purity in an easy to use process, making it well suited for clinical applications in personalised cancer care.
This presentation provides an overview of the company. Key points include:
- The company is a fast growing cancer genetics lab serving oncologists, pathologists, and hospitals.
- Recent acquisition of Clarient is expected to more than double revenue and more than triple adjusted EBITDA in 2016.
- The company has a large addressable market of $5 billion for clinical cancer testing and an experienced management team.
- Financial results show strong revenue and test volume growth as well as expanding adjusted EBITDA margins.
Circulating Tumor Cell, Cell Free DNA, Exosome and Vesicle Cancer Diagnostic ...MarketResearch.com
A revolution in cancer diagnostics is occurring using in vitro blood testing to identify cancer DNA. GRAIL, a new company with impressive backing, has announced a single blood test to detect all cancers. The technology is moving faster than the market. New technology that definitively identifies disease conditions from blood samples is poised to replace expensive invasive surgical biopsy procedures. The market is still in its infancy but has outstanding growth potential. The impact on the health care industry is enormous. The report forecasts the market size out to 2020. In addition, the report looks at potential market sizes by country, by cancer and by the three different opportunities: detection, management and screening.
Investigated the market for cardiovascular medical devices and clinical research organizations (CROs) to understand what roles play in the development and FDA approval process for therapeutics.
This document summarizes clinical trial results for a medical device called dermaPACE that uses shockwave technology to treat diabetic foot ulcers. Some key points:
- A supplemental clinical trial of dermaPACE enrolled 130 patients and showed a complete wound closure rate of 22.7% for those treated with dermaPACE versus 18.3% for controls at 12 weeks.
- When combining results from the original and supplemental trials (total 336 patients), treatment with dermaPACE resulted in a statistically significant higher complete wound closure rate of 37.8% versus 26.2% for controls at 24 weeks.
- Subgroup analyses found higher wound closure rates with dermaPACE treatment for those
This presentation by Pressure BioSciences discusses their Pressure Cycling Technology platform for biological sample preparation. Some key points:
- PCT uses ultra-high pressure to break up cell walls and extract biomolecules, achieving better results than mechanical methods.
- The market for biological sample preparation is multi-billion dollars. PCT addresses the need for improved sample prep methods.
- Over 275 PCT systems have been installed at over 150 customer sites. There are over 100 publications highlighting PCT's advantages.
- Recent accomplishments include a co-marketing agreement with SCIEX, a leader in analytical technologies, and sales of their new Barocycler 2320EXTREME system.
Advanced Medical Isotope Corporation is developing RadioGel, a brachytherapy device, to treat cancers in humans and animals. The company plans to generate near-term revenue from veterinary clinics and international licensing. It is working towards FDA approval for human cancer indications like skin cancer. RadioGel consists of radioactive yttrium-90 phosphate particles delivered via a hydrogel vehicle that solidifies in the body. The company expects to begin sales to veterinary clinics in early 2018 and obtain international licensing revenue. It is led by an experienced management team and advises by world-class medical and scientific boards.
The document provides an overview presentation of NeoGenomics, a cancer genetics testing company. It summarizes NeoGenomics' business model as a pure-play cancer genetics lab focusing on exceptional testing services. It highlights the company's strong historical growth, increasing productivity and operating leverage leading to accelerating cash flow and earnings. The presentation also outlines NeoGenomics' strategy to grow its existing customer base and attract new customers through expanding its test menu and proprietary test development.
- IDXG provides molecular diagnostic tests for cancer risk assessment and prognosis.
- Recent accomplishments include new product launches, reimbursement from Aetna for ThyraMir, and achieving approval in New York State.
- The presentation provides financial information, with revenue growing but losses continuing from investments in sales, R&D and administrative expenses.
This presentation provides an overview of Scythian Biosciences Inc., a pharmaceutical company developing cannabinoid-based drug therapies for traumatic brain injury (TBI). It discusses the large market opportunity for treating TBI, outlines Scythian's solution to develop drugs that inhibit immune response and inflammation following TBI, and presents the company's preclinical and clinical development timelines and leadership team.
Prescient is preparing to commence a Phase 1b/2 clinical trial of PTX-200 in acute myeloid leukemia (AML) at prominent cancer research centers in the United States. PTX-200 is a novel inhibitor of the Akt signaling pathway that has shown promise in overcoming chemotherapy resistance and inducing cancer cell death with fewer toxic side effects than other Akt inhibitors. If successful, the upcoming AML trial could increase interest in Prescient and validate PTX-200 as an improved treatment for this disease with high unmet medical need. Prescient has additional clinical-stage oncology programs in breast cancer, ovarian cancer, and multiple myeloma across its pipeline.
In this NeoGenomics Laboratory Company Overview Presentation 01/09/2014, you will find detail information on the following highlights:
•Fast growing cancer genetics lab servicing Oncologists, Pathologists and Hospitals
•Strategic client partnerships created by “Tech-Only” model
•Dynamic, rapidly-growing and consolidating industry
•Industry-leading revenue & test volume growth
•Strong productivity and operating leverage leading to accelerating cash flow and net income
•Strong Management Team with large cap lab experience
In this NeoGenomics Laboratory Company Overview Presentation 01/09/2014, you will find detail information on the following highlights:
•Fast growing cancer genetics lab servicing Oncologists, Pathologists and Hospitals
•Strategic client partnerships created by “Tech-Only” model
•Dynamic, rapidly-growing and consolidating industry
•Industry-leading revenue & test volume growth
•Strong productivity and operating leverage leading to accelerating cash flow and net income
•Strong Management Team with large cap lab experience
- The company provides an overview presentation of its business operations as a fast growing cancer genetics laboratory.
- Key highlights include strategic client partnerships through its "tech-only" model, an industry-leading growth rate in revenue and test volume, and the most comprehensive cancer testing menu in the industry.
- The acquisition of Clarient is expected to more than double the company's revenue and more than triple adjusted EBITDA for 2016.
- The company provides an overview presentation of its business operations, growth strategy, and recent acquisition of Clarient, which is expected to more than double its revenue and more than triple its adjusted EBITDA in 2016.
- Key highlights include its focus on being a leading cancer genetics testing provider, experience in consolidating the industry, a comprehensive testing menu, and strategic partnerships with pathologists and oncologists.
- Financial projections estimate the combined company will generate around $247 million in revenue and $35-40 million in adjusted EBITDA in 2016 following the acquisition.
- The company provides an overview presentation of its business operations, growth strategy, and recent acquisition of Clarient, which is expected to more than double its revenue and more than triple its adjusted EBITDA in 2016.
- Key highlights include its focus on cancer genetics testing, strategic partnerships with pathologists and oncologists, a comprehensive testing menu, and experienced management team.
- Financial projections estimate combined pro forma revenue of $242-252 million and adjusted EBITDA of $35-40 million in 2016 following the acquisition of Clarient. Synergies from the acquisition are expected to provide $20-30 million in annual cost savings.
This presentation provides an overview of a cancer genetics laboratory company. Key points include:
- The company has experienced strong and consistent revenue and test volume growth through strategic partnerships and an expanding test menu. An upcoming acquisition is expected to more than double revenue and more than triple adjusted EBITDA.
- The management team has extensive experience in large cap clinical laboratories.
- The company addresses a $5 billion clinical cancer testing market and has opportunities for further growth through innovation, such as liquid biopsy tests and partnerships with oncologists.
- Recent acquisitions and an expanding test menu have contributed to accelerating same store sales growth.
- NeoGenomics is a pure-play cancer genetics testing company that has experienced fast revenue and test volume growth through expanding its test menu and increasing sales force productivity. Its "tech-only" business model focuses on partnerships with oncologists and hospitals to provide genetic testing services.
- The company has consistently grown its annual revenue and tests performed historically through new test innovations, a growing sales force, and greater productivity. It is targeting further market share gains and operating leverage to accelerate cash flow and earnings growth.
NeoGenomics provides cancer genetic testing services to oncologists, pathologists, and hospitals. It has experienced strong and consistent growth in revenue and tests performed annually through expanding its test menu, increasing sales force productivity, and gaining market share. The company aims to continue its growth by launching new tests, pursuing partnerships and acquisitions, and capitalizing on the large and growing market for cancer genetic testing fueled by an aging population and advancements in targeted therapies.
This presentation provides an overview of NeoGenomics, a cancer genetics testing company. Key points include:
- NeoGenomics has experienced strong and consistent growth in revenue and test volume historically through strategic partnerships and an expanding test menu.
- The company focuses on fast turnaround times and exceptional client service to drive continued growth.
- Management aims to increase market share and profitability through expanding sales coverage, new test offerings like next generation sequencing, and potential M&A opportunities.
- NeoGenomics seeks to capitalize on favorable industry trends like an aging population, rise of personalized medicine, and consolidation in the cancer diagnostics field.
The presentation provides an overview of NeoGenomics, a cancer genetic testing company. It highlights the company's consistent historical growth in tests performed and revenue. The management team has significant experience in large cap clinical laboratories. The company aims to continue expanding its test menu and market share through new product development and partnerships within the fast-growing cancer genetic testing industry.
In this NeoGenomics Laboratory Company Overview Presentation 02/19/2014, you will find detail information on the following highlights:
•Fast growing cancer genetics lab servicing Oncologists, Pathologists and Hospitals
•Strategic client partnerships created by “Tech-Only” model
•Dynamic, rapidly-growing and consolidating industry
•Industry-leading revenue & test volume growth
•Strong productivity and operating leverage leading to accelerating cash flow and net income
•Strong Management Team with large cap lab experience
Liquid biopsy from a simple blood test enabling personalised cancer care | Sh...ANGLE plc
Liquid biopsy from a simple blood test is enabling personalised cancer care. The Parsortix system from ANGLE can harvest cancer cells from blood (liquid biopsy) in a non-invasive and repeatable way. This provides a new approach to obtaining cancer cells for analysis compared to traditional tumour biopsies. Key opinion leaders have evaluated the Parsortix system and found that it captures all types of cancer cells with high purity in an easy to use process, making it well suited for clinical applications in personalised cancer care.
This presentation provides an overview of the company. Key points include:
- The company is a fast growing cancer genetics lab serving oncologists, pathologists, and hospitals.
- Recent acquisition of Clarient is expected to more than double revenue and more than triple adjusted EBITDA in 2016.
- The company has a large addressable market of $5 billion for clinical cancer testing and an experienced management team.
- Financial results show strong revenue and test volume growth as well as expanding adjusted EBITDA margins.
Circulating Tumor Cell, Cell Free DNA, Exosome and Vesicle Cancer Diagnostic ...MarketResearch.com
A revolution in cancer diagnostics is occurring using in vitro blood testing to identify cancer DNA. GRAIL, a new company with impressive backing, has announced a single blood test to detect all cancers. The technology is moving faster than the market. New technology that definitively identifies disease conditions from blood samples is poised to replace expensive invasive surgical biopsy procedures. The market is still in its infancy but has outstanding growth potential. The impact on the health care industry is enormous. The report forecasts the market size out to 2020. In addition, the report looks at potential market sizes by country, by cancer and by the three different opportunities: detection, management and screening.
Investigated the market for cardiovascular medical devices and clinical research organizations (CROs) to understand what roles play in the development and FDA approval process for therapeutics.
This document summarizes clinical trial results for a medical device called dermaPACE that uses shockwave technology to treat diabetic foot ulcers. Some key points:
- A supplemental clinical trial of dermaPACE enrolled 130 patients and showed a complete wound closure rate of 22.7% for those treated with dermaPACE versus 18.3% for controls at 12 weeks.
- When combining results from the original and supplemental trials (total 336 patients), treatment with dermaPACE resulted in a statistically significant higher complete wound closure rate of 37.8% versus 26.2% for controls at 24 weeks.
- Subgroup analyses found higher wound closure rates with dermaPACE treatment for those
This presentation by Pressure BioSciences discusses their Pressure Cycling Technology platform for biological sample preparation. Some key points:
- PCT uses ultra-high pressure to break up cell walls and extract biomolecules, achieving better results than mechanical methods.
- The market for biological sample preparation is multi-billion dollars. PCT addresses the need for improved sample prep methods.
- Over 275 PCT systems have been installed at over 150 customer sites. There are over 100 publications highlighting PCT's advantages.
- Recent accomplishments include a co-marketing agreement with SCIEX, a leader in analytical technologies, and sales of their new Barocycler 2320EXTREME system.
Advanced Medical Isotope Corporation is developing RadioGel, a brachytherapy device, to treat cancers in humans and animals. The company plans to generate near-term revenue from veterinary clinics and international licensing. It is working towards FDA approval for human cancer indications like skin cancer. RadioGel consists of radioactive yttrium-90 phosphate particles delivered via a hydrogel vehicle that solidifies in the body. The company expects to begin sales to veterinary clinics in early 2018 and obtain international licensing revenue. It is led by an experienced management team and advises by world-class medical and scientific boards.
The document provides an overview presentation of NeoGenomics, a cancer genetics testing company. It summarizes NeoGenomics' business model as a pure-play cancer genetics lab focusing on exceptional testing services. It highlights the company's strong historical growth, increasing productivity and operating leverage leading to accelerating cash flow and earnings. The presentation also outlines NeoGenomics' strategy to grow its existing customer base and attract new customers through expanding its test menu and proprietary test development.
- IDXG provides molecular diagnostic tests for cancer risk assessment and prognosis.
- Recent accomplishments include new product launches, reimbursement from Aetna for ThyraMir, and achieving approval in New York State.
- The presentation provides financial information, with revenue growing but losses continuing from investments in sales, R&D and administrative expenses.
This presentation provides an overview of Scythian Biosciences Inc., a pharmaceutical company developing cannabinoid-based drug therapies for traumatic brain injury (TBI). It discusses the large market opportunity for treating TBI, outlines Scythian's solution to develop drugs that inhibit immune response and inflammation following TBI, and presents the company's preclinical and clinical development timelines and leadership team.
Prescient is preparing to commence a Phase 1b/2 clinical trial of PTX-200 in acute myeloid leukemia (AML) at prominent cancer research centers in the United States. PTX-200 is a novel inhibitor of the Akt signaling pathway that has shown promise in overcoming chemotherapy resistance and inducing cancer cell death with fewer toxic side effects than other Akt inhibitors. If successful, the upcoming AML trial could increase interest in Prescient and validate PTX-200 as an improved treatment for this disease with high unmet medical need. Prescient has additional clinical-stage oncology programs in breast cancer, ovarian cancer, and multiple myeloma across its pipeline.
In this NeoGenomics Laboratory Company Overview Presentation 01/09/2014, you will find detail information on the following highlights:
•Fast growing cancer genetics lab servicing Oncologists, Pathologists and Hospitals
•Strategic client partnerships created by “Tech-Only” model
•Dynamic, rapidly-growing and consolidating industry
•Industry-leading revenue & test volume growth
•Strong productivity and operating leverage leading to accelerating cash flow and net income
•Strong Management Team with large cap lab experience
In this NeoGenomics Laboratory Company Overview Presentation 01/09/2014, you will find detail information on the following highlights:
•Fast growing cancer genetics lab servicing Oncologists, Pathologists and Hospitals
•Strategic client partnerships created by “Tech-Only” model
•Dynamic, rapidly-growing and consolidating industry
•Industry-leading revenue & test volume growth
•Strong productivity and operating leverage leading to accelerating cash flow and net income
•Strong Management Team with large cap lab experience
Specialized oncology reference laboratory providing the latest testing technologies, global/tech-only options, and interactive education to the pathology community
Offer the complete spectrum of diagnostic services through nationwide network of laboratories
Dedicated to providing superior service, faster turn-around times, and complete attention to the needs of our clients and their patients
NeoGenomics Forward-looking statements, Investment Highlights, Consistent Historical Growth, Accelerating Cash FLow & Earnings, Management Team, Cancer Testing Services, Customer Targets, NeoGenomics Formula for Success, Industry Dynamics, US Cancer Testing Market Size, Cancer Testing Market Characteristics, Key Growth Drivers Over the Next 3 Years...
NeoGenomics Company Overview highlights. It includes investment highlights, Consistent historical growth charts, accelerating cash flow & earnings, management team, testing services, customer targets, formula for success, industry dynamics, U.S. cancer market size, cancer testing market characteristics, key growth drivers...
NeoGenomics overview presetnation ontains statements which constitute forward-looking statements within the meaning of Section 27A of the Securities Act, as amended; Section 21E of the Securities Exchange Act of 1934; and the Private Securities Litigation Reform Act of 1995. The words “may”, “would”, “could”, “will”, “expect”, “estimate”, “anticipate”, “believe”, “intend”, “plan”, “goal”, and similar expressions and variations thereof are intended to specifically identify forward-looking statements. All statements that are not statements of historical fact are forward-looking statements.
This presentation contains statements which constitute forward-looking statements within the meaning of Section 27A of the Securities Act, as amended; Section 21E of the Securities Exchange Act of 1934; and the Private Securities Litigation Reform Act of 1995. The words “may”, “would”, “could”, “will”, “expect”, “estimate”, “anticipate”, “believe”, “intend”, “plan”, “goal”, and similar expressions and variations thereof are intended to specifically identify forward-looking statements. All statements that are not statements of historical fact are forward-looking statements.
Investors and prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those projected in the forward-looking statements as a result of various factors. The risks that might cause such differences are identified in our filings with the Securities and Exchange Commission. We undertake no obligation to publicly update or revise the forward looking statements made in this presentation to reflect events or circumstances after
This presentation provides an overview of NeoGenomics, a cancer genetic testing company. Key points include:
- NeoGenomics has experienced consistent historical growth in the number of cancer tests performed and annual revenue.
- The company focuses on fast-growing cancer genetics testing and has strategic partnerships with oncologists and hospitals.
- Management aims to continue expanding the test menu and achieving operating leverage to accelerate cash flow and earnings.
Cancer Diagnostics Reference Laboratory / NeoGenomics April 2014 investors company overview presentation. This presentation highlights the following:
--Fast growing cancer genetics lab servicing Oncologists, Pathologists and Hostpitals
--Strategic client partnerships created by "Tech-Only" model
--Dynamic, rapidly-growing and consolidating industry
Industry-leading revenue & test volume growth
--Strong productivity and operating leverage leading to accelerating cash flow and net income
--Strong Management Team with large cap lab experience
This company presentation provides an overview of NeoGenomics and their cancer genetic testing services. Some key points:
- NeoGenomics is a fast-growing cancer genetics lab that services oncologists, pathologists, and hospitals through strategic partnerships and a tech-only model.
- They have an experienced management team with experience at large cap labs and offer the most comprehensive cancer testing menu in the industry.
- NeoGenomics has demonstrated a proven track record of consistent growth over the last 10 years with 65% CAGR in revenue and test volume.
- Their focus for 2015 includes expanding next generation sequencing, developing a prostate cancer liquid biopsy test, launching new products, and growing their clinical trials business
This presentation provides an overview of the company, which provides cancer genetic testing services. It highlights the company's fast growth, experienced management team, expanding product and service offerings including next generation sequencing and liquid biopsy tests. The company has achieved significant reductions in costs per test through economies of scale and innovation. Financial metrics show accelerating revenue, earnings, and cash flow in recent years through both organic growth and acquisition.
This document provides an overview of a cancer genetic testing company. It discusses the company's growth in revenue and test volume over the past 10 years at a 70% compound annual growth rate. The management team is experienced from large cap labs and is focused on innovation, growth, cost reductions, and becoming more digital. The testing market is large at $10-12 billion and the company has a growing test menu and facility footprint across the United States.
This document provides an overview of a cancer genetic testing company. It discusses the company's growth in revenue and test volume over the past 10 years at a 70% compound annual growth rate. The management team is experienced in large cap laboratories. The company provides a wide range of genetic testing services and has launched over 90 new assays in recent years. It has expanded its facilities and geographic footprint through acquisitions.
Specialized oncology reference laboratory providing the latest testing technologies, global/tech-only options, and interactive education to the pathology community
Offer the complete spectrum of diagnostic services through nationwide network of laboratories
Dedicated to providing superior service, faster turn-around times, and complete attention to the needs of our clients and their patients
Company Overview Presentation for NeoGenomics:
•Fast growing cancer genetics lab servicing Oncologists, Pathologists and Hospitals
•Strategic client partnerships created by “Tech-Only” model
•Dynamic, rapidly-growing and consolidating industry
•Industry-leading revenue & test volume growth
•Strong productivity and operating leverage leading to accelerating cash flow and net income
•Strong Management Team with large cap lab experience
NeoGenomics Company Overview presents investment highlights. It provides details on its growing cancer genetics lab servicing oncologists, pathologists and hospitals, its strategic client partnerships, its dynamic, rapidly-growing and consolidating industry and much more…
NeoGenomics Company Overview 07/24/2014. An emerging leader in fastest-growing segment of lab testing industry. They hold a robust competitive advantages and product portfolio. They have a strong management team with outstanding industry experience.
Sutro Biopharma is conducting a Phase 1 clinical trial of STRO-002, an antibody-drug conjugate (ADC) targeting folate receptor alpha (FolRα), in patients with advanced platinum-resistant or refractory epithelial ovarian cancer, fallopian tube or primary peritoneal cancers. Interim data from the trial will be presented at the AACR virtual conference on April 27th. STRO-002 was designed using Sutro's proprietary protein engineering platform, XpressCF, to have improved stability and a widened therapeutic index compared to other FolRα-targeting ADCs. Preclinical studies demonstrated STRO-002's enhanced potency and specificity versus benchmarks. The trial will evaluate
This presentation provides an overview of Interpace Diagnostics Group (IDXG), a commercial company that provides molecular diagnostic tests and pathology services for cancer evaluation. IDXG operates two CLIA-certified labs and has four proprietary molecular diagnostic tests for pancreatic cysts and thyroid nodules that assess cancer risk. The tests have high margins and barriers to entry due to reimbursement and complexity. Recent accomplishments include raising funds, improving financials, expanding insurance coverage and launching international distribution. The molecular diagnostic market is large and growing due to advantages over drug development. IDXG's tests establish new standards in cancer risk assessment for pancreatic cysts and thyroid nodules compared to current guidelines.
Similar to March 2017 Company Overview Presentation by NeoGenomics, (Nasdaq: NEO) a fast growing cancer genetic testing lab traded on Nasdaq. (20)
Breast cancer: Post menopausal endocrine therapyDr. Sumit KUMAR
Breast cancer in postmenopausal women with hormone receptor-positive (HR+) status is a common and complex condition that necessitates a multifaceted approach to management. HR+ breast cancer means that the cancer cells grow in response to hormones such as estrogen and progesterone. This subtype is prevalent among postmenopausal women and typically exhibits a more indolent course compared to other forms of breast cancer, which allows for a variety of treatment options.
Diagnosis and Staging
The diagnosis of HR+ breast cancer begins with clinical evaluation, imaging, and biopsy. Imaging modalities such as mammography, ultrasound, and MRI help in assessing the extent of the disease. Histopathological examination and immunohistochemical staining of the biopsy sample confirm the diagnosis and hormone receptor status by identifying the presence of estrogen receptors (ER) and progesterone receptors (PR) on the tumor cells.
Staging involves determining the size of the tumor (T), the involvement of regional lymph nodes (N), and the presence of distant metastasis (M). The American Joint Committee on Cancer (AJCC) staging system is commonly used. Accurate staging is critical as it guides treatment decisions.
Treatment Options
Endocrine Therapy
Endocrine therapy is the cornerstone of treatment for HR+ breast cancer in postmenopausal women. The primary goal is to reduce the levels of estrogen or block its effects on cancer cells. Commonly used agents include:
Selective Estrogen Receptor Modulators (SERMs): Tamoxifen is a SERM that binds to estrogen receptors, blocking estrogen from stimulating breast cancer cells. It is effective but may have side effects such as increased risk of endometrial cancer and thromboembolic events.
Aromatase Inhibitors (AIs): These drugs, including anastrozole, letrozole, and exemestane, lower estrogen levels by inhibiting the aromatase enzyme, which converts androgens to estrogen in peripheral tissues. AIs are generally preferred in postmenopausal women due to their efficacy and safety profile compared to tamoxifen.
Selective Estrogen Receptor Downregulators (SERDs): Fulvestrant is a SERD that degrades estrogen receptors and is used in cases where resistance to other endocrine therapies develops.
Combination Therapies
Combining endocrine therapy with other treatments enhances efficacy. Examples include:
Endocrine Therapy with CDK4/6 Inhibitors: Palbociclib, ribociclib, and abemaciclib are CDK4/6 inhibitors that, when combined with endocrine therapy, significantly improve progression-free survival in advanced HR+ breast cancer.
Endocrine Therapy with mTOR Inhibitors: Everolimus, an mTOR inhibitor, can be added to endocrine therapy for patients who have developed resistance to aromatase inhibitors.
Chemotherapy
Chemotherapy is generally reserved for patients with high-risk features, such as large tumor size, high-grade histology, or extensive lymph node involvement. Regimens often include anthracyclines and taxanes.
- Video recording of this lecture in English language: https://youtu.be/Pt1nA32sdHQ
- Video recording of this lecture in Arabic language: https://youtu.be/uFdc9F0rlP0
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Kosmoderma Academy, a leading institution in the field of dermatology and aesthetics, offers comprehensive courses in cosmetology and trichology. Our specialized courses on PRP (Hair), DR+Growth Factor, GFC, and Qr678 are designed to equip practitioners with advanced skills and knowledge to excel in hair restoration and growth treatments.
Summer is a time for fun in the sun, but the heat and humidity can also wreak havoc on your skin. From itchy rashes to unwanted pigmentation, several skin conditions become more prevalent during these warmer months.
DECLARATION OF HELSINKI - History and principlesanaghabharat01
This SlideShare presentation provides a comprehensive overview of the Declaration of Helsinki, a foundational document outlining ethical guidelines for conducting medical research involving human subjects.
Osteoporosis - Definition , Evaluation and Management .pdfJim Jacob Roy
Osteoporosis is an increasing cause of morbidity among the elderly.
In this document , a brief outline of osteoporosis is given , including the risk factors of osteoporosis fractures , the indications for testing bone mineral density and the management of osteoporosis
Histololgy of Female Reproductive System.pptxAyeshaZaid1
Dive into an in-depth exploration of the histological structure of female reproductive system with this comprehensive lecture. Presented by Dr. Ayesha Irfan, Assistant Professor of Anatomy, this presentation covers the Gross anatomy and functional histology of the female reproductive organs. Ideal for students, educators, and anyone interested in medical science, this lecture provides clear explanations, detailed diagrams, and valuable insights into female reproductive system. Enhance your knowledge and understanding of this essential aspect of human biology.
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotesPsychoTech Services
A proprietary approach developed by bringing together the best of learning theories from Psychology, design principles from the world of visualization, and pedagogical methods from over a decade of training experience, that enables you to: Learn better, faster!
These lecture slides, by Dr Sidra Arshad, offer a simplified look into the mechanisms involved in the regulation of respiration:
Learning objectives:
1. Describe the organisation of respiratory center
2. Describe the nervous control of inspiration and respiratory rhythm
3. Describe the functions of the dorsal and respiratory groups of neurons
4. Describe the influences of the Pneumotaxic and Apneustic centers
5. Explain the role of Hering-Breur inflation reflex in regulation of inspiration
6. Explain the role of central chemoreceptors in regulation of respiration
7. Explain the role of peripheral chemoreceptors in regulation of respiration
8. Explain the regulation of respiration during exercise
9. Integrate the respiratory regulatory mechanisms
10. Describe the Cheyne-Stokes breathing
Study Resources:
1. Chapter 42, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 36, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 13, Human Physiology by Lauralee Sherwood, 9th edition
NAVIGATING THE HORIZONS OF TIME LAPSE EMBRYO MONITORING.pdfRahul Sen
Time-lapse embryo monitoring is an advanced imaging technique used in IVF to continuously observe embryo development. It captures high-resolution images at regular intervals, allowing embryologists to select the most viable embryos for transfer based on detailed growth patterns. This technology enhances embryo selection, potentially increasing pregnancy success rates.
10 Benefits an EPCR Software should Bring to EMS Organizations Traumasoft LLC
The benefits of an ePCR solution should extend to the whole EMS organization, not just certain groups of people or certain departments. It should provide more than just a form for entering and a database for storing information. It should also include a workflow of how information is communicated, used and stored across the entire organization.
2. 2
Forward-looking Statements
This presentation contains statements which constitute forward-looking statements within the
meaning of Section 27A of the Securities Act, as amended; Section 21E of the Securities Exchange
Act of 1934; and the Private Securities Litigation Reform Act of 1995. The words “may”, “would”,
“could”, “will”, “expect”, “estimate”, “anticipate”, “believe”, “intend”, “plan”, “goal”, and similar
expressions and variations thereof are intended to specifically identify forward-looking
statements. All statements that are not statements of historical fact are forward-looking
statements.
Investors and prospective investors are cautioned that any such forward-looking statements are
not guarantees of future performance and involve risks and uncertainties, and that actual results
may differ materially from those projected in the forward-looking statements as a result of various
factors. The risks that might cause such differences are identified in our filings with the Securities
and Exchange Commission. We undertake no obligation to publicly update or revise the forward
looking statements made in this presentation to reflect events or circumstances after the date of
this presentation or to reflect the occurrence of unanticipated events.
3. 3
Investment Highlights
Leading pure-play oncology testing company
Unique client partnership business model
History of strong clinical growth & rapid innovation
Favorable demographics driving expanding market
Increasing momentum in Pharma Services
Realization of Clarient cost synergies accelerating
Significant opportunities for market share gains and
Adjusted EBITDA expansion
4. 4
Financial Facts
NASDAQ Ticker: NEO
Stock Price (6/5/17): $7.78
Basic Shares Outstanding: 79.2 MM
Avg. Daily Volume (3 Mos.): 372K
52 Week Low/High: $6.90/9.88
% Held by Insiders: 17.5%
Market Cap (6/5/17) $616.5 MM
Debt (MRQ) 111.0
Preferred Stock (Redemption Value) 46.6
Less Cash (MRQ) (11.0)
Enterprise Value $763.1 MM
EV/ 2017 Consensus Rev 2.9x
Recent Financial Performance
($,MMs)
Recent Financial Performance FY 2016
YoY
% Chg. *
Clinical Testing Rev $222.0 124%
Pharma Service Rev 22.1 1,728%
Total Revenue 244.1 145%
Adjusted EBITDA $34.7 259%
% EBITDA Margin 14.2% +450bps
* % Change includes the effects of Clarient Acquisition.
Stock Information Market Capitalization & Enterprise Value
2016 Financial Highlights5 Year Stock Price Performance
5. 5
Proven Management Team
• Combination of industry-experienced medical, financial and technical professionals
• Integral role in the Company’s industry leading operating model and unrivaled growth trajectory
• Instrumental to the successful integration of the Clarient Acquisition
Position NEO Experience Industry Experience
Douglas VanOort Chief Executive Officer 8 years 35 years
Maher Albitar, M.D. SVP & Chief Medical Officer 5 years 26 years
Robert Shovlin President of Clinical Services Division 3 years 20 years
Steven Jones Executive Vice President 15 years 15 years
George Cardoza SVP & Chief Financial Officer 8 years 23 years
Jennifer Balliet Chief Culture Officer 9 years 9 years
Steven Ross Chief Information Officer 3 years 3 years
Denise Pedulla General Counsel 2 years 21 years
Bill Bonello Vice President, Treasurer & Dir. of Corp. Dev. <1 year 10 years
Steven Brodie, Ph.D., FACMG Vice President of Operations 8 years 14 years
Fred Weidig
Vice President, Finance & Principal
Accounting Officer
10 years 10 years
6. NEO’s Proven Track Record of Consistent Growth
Clinical Genetic Testing Annual Revenue Clinical Genetic Tests Performed
($, 000s)
* Base NEO represents organic revenue and test volume growth from legacy business and excludes the impacts from the PathLogic and Clarient acquisitions.
6
$558 $1,885
$6,476
$11,505
$20,015
$29,469
$34,371
$43,484
$59,866
$66,467
$82,194
$188,374
$214,708
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
Pro Forma Clarient 2015 Genetic Test Revenue
NEO Clinical Genetic Testing Revenue
1,152
4,082
12,838
20,998
32,539
45,675
57,332
76,288
114,606
137,317
177,279
490,450
563,132
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
Pro Forma Clarient 2015 Clinical Genetic Tests
NEO Clincial Genetic Tests Performed
7. 7
Growth Goals
• Mid-teens organic clinical volume growth
• 20%+ organic Pharma revenue growth
• 25-35% incremental Adj. EBITDA on revenue growth
Driven by:
− Comprehensive test menu – “One-Stop Shop”
− Innovation in test development
− Demographics and medical advances
− Increased efficiencies
8. Strong Track Record of Innovation
Leader in FISH, Flow Cytometry, IHC, Molecular, Immuno-Oncology
(PD-L1) and Emerging Leader in Liquid Biopsy Testing!
70 new/revised tests, incl:
NeoLABTM Liquid Biopsies
• MDS/CMML Profile
• AML Profile
• FLT3 Mutation Analysis
• NPM1 Mutation Analysis
• PML-RARA Translocation
• RUNX1-RNX1T1Transloc
• INV16 Translocation
• c-kit Mutation Analysis
• IDH1 Mutation Analysis
• IDH2 Mutation Analysis
• NRAS Mutation Analysis
• KRAS Mutation Analysis
• BTK Inhibitor Resistance
• Solid Tumor Monitoring
Germline MolDx Testing
• BRCA1 & BRCA2
• Lynch Syndrome (colon)
• 73 Gene Comprehensive
Predisposition Panel
Other
• ALK, ROS1, RET Fusion
• Sarcoma gene Fusion
• NeoSITE Cervical FISH
• Expanded IHC Menu
• Smart Flow Cytometry
• 10-color Flow Cytometry
• Implemented Adv MolDx
platform in lieu of Kits
• 28 new Molecular Assays
• Proprietary method for
increasing sensitivity of Sanger
sequencing
• 7 NeoTYPE MolDx Panels
• SVM for FISH (Patent App)
• Barrett’s Esoph. FISH (Patent
App)
• NeoARRAY/SNP Cytogenetics
• Internalized send-outs
40 new Molecular tests, incl:
• Add’l NeoTYPE Panels
• Next Generation
Sequencing (48 genes)
• ROS1 FISH
• NeoSITE Melanoma FISH
• Plasma/Urine-based Prostate
Test (Patent App)
• SVM-based Cytogenetics
Analysis System
• SVM-based Automated FISH
Analysis System v2
• Began development of
NeoLAB (Liquid Alternative
to Biopsy) Prostate Cx test
60 new/revised tests, incl:
• 24 new NeoTYPE Next
Generation Sequencing
Profiles
• 26 new IHC/ISH tests
• Additional NeoLAB Prostate
clinical studies
• AML Extended FISH Panel
• AML Favorable-Risk FISH Panel
• MDS Extended FISH Panel
• Plasma Cell Myeloma Risk
Stratification FISH Panel
• RET FISH
• MET FISH
• ALL Adult & Pediatric FISH
Panels
• HER2 Breast Equivocal FISH
Panel
• BRAF Translocation FISH
• Chromosome 1 POC Ploidy
• Launched robotic FISH-Cyto
processing platform
50 new/revised tests, incl:
• Comprehensive PD-L1 Testing
(three FDA-cleared and one LDT)
• 1,385 genes RNA-Based Pan
Cancer NGS Fusion, Mutation
and Expression Profiling.
• Smart Flow Cytometry data
analysis platform
• Pediatric Hereditary Susceptibility
• Hereditary DNA Panel (prostate)
• Inherited Bone Marrow Failure
• MET Exon 14 Deletion Analysis
• NRAS Exon 4 Mutation Analysis
• NGS ALK, NTRK, RET, ROS1 Fusion
NeoLABTM Liquid Biopsies
• NeoLAB Myeloid Disorders Profile
• EGFR T790M
NeoTYPETM Multi Modality Profiles
• AITL/Peripheral T-Cell Lymphoma
• Thyroid Profile
• Brain Tumor Profile
• Melanoma Profile
• Liposarcoma Fusion Profile
• Head & Neck Tumor Profile
FISH & IHC
• FISH Testing for EWSR1, SS18,
DDIT3, STAT 6, BCL2, & TCL1
• IHC Testing for CXCL13, BAP1,
INI1, MUC4
• PD-LI
2012
2013
2014
2015
2016
8
9. Positive Demographic Tailwinds and ….
Shifting Demographics Incidence of Cancer by Age
0.0
20.0
40.0
60.0
80.0
100.0
120.0
Age 60-64 Age 65-74 Age 75-84 Age 85+
1.0%
2.7%
5.1%
13.8%
24.4%
26.2%
18.8%
7.9%
< 20 20-34 35-44 45-54 55-64 65-74 74-84 > 84
Source: United States Census Bureau Source: National Cancer Institute
9
10. Rapidly Growing Market Opportunity
Source: National Institutes of Health (NIH)
10
• Aging Population –
incidence increases with age
• Increased Prevalence –
better treatments lead to
more survivors and
monitoring
• Scientific advances – driving
targeted therapeutics
• Increased cost of drugs –
more careful triage and
monitoring
11. Positions NEO for Additional Market Share Gains
11
• Based on CMS Data, the Cancer
Market was $5.1B in 2014
• Assuming modest growth, the
Cancer Market is about $6B in 2017
• NeoGenomics 2017 Revenue
estimate of $260M --- about 5% of
the market
• Industry is highly fragmented – and
is expected to consolidate further
over time
12. Opportunities by Customer Type
Pathologists & Hospitals (about 80% of Revenue)
• Large Market with 5,600 Hospitals in U.S., and 18,000 active Pathologists
• Enable Pathologists to practice using sophisticated tools/tests and “tech-only” services
• Unique ability to be “One-stop shop” with comprehensive oncology test menu
• Competitive pricing under contract, and agreements with hospitals & hospital GPOs
Oncologists, Hematologists & Clinicians (about 10% of Revenue)
• Disease Panels, liquid biopsies, and comprehensive molecular menus
• Increasing opportunity to service larger practices with Partnership-based tech-only model
• Contracts with key Managed Care organizations
Pharma Services & Other (about 10% of Revenue)
• Contract research/clinical trial support work for Pharma clients
• Opening in Geneva, Switzerland to handle European and Global studies
• MultiOmyx platform is a unique offering gaining acceptance by Pharma firms
12
13. Evolution of Payer Mix For Clinical Testing
Medicare reimbursements have fallen from 52% of payer mix in 2010 to 16% in 2016!
(1) 2016 is a blended average estimate of the Base NEO and Clarient payer mixes.
13
52%
44%
37%
27%
21% 21%
16%
23%
26%
34%
45%
51%
59%
58%
23%
29% 28% 28% 29%
20%
26%
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
2010 2011 2012 2013 2014 2015 2016
Medicare (Incl. Medicaid) Client Bill (Hospitals) Commercial Insurance Other/Accruals/Pt. Pay
(1)
15. 15
Historically Steady Margins Despite Lower Avg. Unit Prices*
* To facilitate comparison, all data is for Clinical Genetic Testing and excludes the impact from the PathLogic acquisition and Pharma Services.
(1) Productivity calculated as the average number of lab tests completed per month per laboratory FTE.
45.9%
44.7%
44.8%
47.7% 48.0%
46.1%
47.2%
-40.9%
65.6%
-50%
-40%
-30%
-20%
-10%
0%
10%
20%
30%
40%
50%
60%
70%
35%
40%
45%
50%
55%
2010 2011 2012 2013 2014 2015 2016
Gross Margin % From Clinical Genetic Testing Cum Change in Avg Rev/ Clinical Genetic Test Since 2009
Cum Change in Productivity Since 2009
CumChangeinAvgRev/Test&Productivity
(1)
16. Clarient Cost Synergies and Opportunities
16
2015 Adjusted EBITDA
NeoGenomics $ 9.7 MM
Clarient Pro Forma $ 9.2 MM
Pro Forma Combined $18.9 MM
2016 “New Neo” EBITDA $ 34.7 MM
Clearly, “synergies” showed up in 2016 --- and there are more to be realized in 2017- 18
2017 – 2018 Opportunities:
• Laboratory facilities consolidated on 3/26/17 – teams now working as one
• Ability to run combined batches in So. California rather than two batches
• Ongoing supplier re-negotiations as contracts end – we have 2x volume
• Irvine laboratory closed on 4/30 – saving over $50k per month
• Cross selling now possible – accounts all on one laboratory information system
• Pharma services just starting to access Neo’s leading Molecular menu
“9 + 9 equals 34”
17. Growing Pharma Services
$41.6mm Backlog as of 3/31/17 - Approx. 400 active projects from 100+ Clients
• 50% of projects in pre-clinical space – often leading to more lucrative Phase I, II, and III work
• Major PD-L1 testing site for Keytruda (Merck) and Opdivo (BMS) – Leader in Immuno-Oncology
• Medical and Scientific expertise, comprehensive test menu, & extensive clinical network
• International presence in 2017 with Geneva, Switzerland Lab
17
19. Recent Financial Information (P&L)
($, 000's) 2014(1) 2015(2)(3) 2016(3) Q1 2016 Q1 2017(4)
Total Revenue $ 87,069 $ 99,802 $ 244,083 $ 59,704 $ 61,676
% Growth (YoY) 31.0% 14.6% 144.6% 159.3% 3.3%
Total Gross Profit 40,714 43,756 110,379 27,173 27,196
Gross Margin % 46.8% 43.8% 45.2% 45.5% 44.1%
Total SG&A (Incl R&D) Exp(3) 38,496 49,391 107,804 25,251 27,311
SG&A as a % of Rev 44.2% 49.5% 44.2% 42.3% 44.3%
Adjusted Net Income/(Loss)* 2,689 4,042 14,399 $ 2,884 $ 2,552
Adjusted Diluted EPS* $0.05 $0.06 $0.15 $0.03 $0.03
Adjusted EBITDA* $ 9,176 $ 9,672 $ 34,685 $ 8,236 $ 7,070
% Growth 7.8% 9.7% 258.4% 442.2% -14.2%
Operating Data(5)
% Growth in Clinical Genetic Tests (YoY) 29.1% 25.6% 154.6% 174.7% 15.3%
Avg. Revenue/Clinical Genetic Test $ 464 $ 412 $ 381 $ 391 $ 354
% Change (YoY) -4.2% -11.2% -6.8% -6.1% -9.4%
Avg. COGS/Clinical Genetic Test $ 241 $ 220 $ 201 $ 206 $ 186
% Change (YoY) -4.7% -8.6% -8.7% -12.7% -9.7%
* See Appendix for definitions of Adj. EBITDA, Adj. Net Income and Adj. Diluted EPS as well as a reconciliation of GAAP Net Income to Adjusted financial information.
(1) 2014 figures include the results of PathLogic from the date of the acquisition on July 8, 2014.
(2) 2015 figures include the results of Clarient for two days from the date of the acquisition on December 30, 2015 and $4.7 MM of Clarient transaction expenses in SG&A.
(3) 2016 SG&A includes 7.4 MM of one-time bank debt retirement fees and impairment charges.
(4) Q1 2017 SG&A includes $0.4 MM of one-time expenses associated with the move of NeoGenomics Irvine, CA facility into its Aliso Viejo, CA facility.
(5) All Operating data refers to Clinical Genetic Testing and excludes the results from PathLogic and the Pharma Services Division.
19
20. Confidential
2017 Revenue Bridge(1)
(1) Based on guidance issued 4/26/17 ($, MMs)
We estimate revenue of $255 – $265 million in 2017…
20
• NEO estimates that growth in the clinical business will be impacted by approximately $4 MM of
distractions related to the Clarient Integration activities and approximately $1.8 MM of cuts to
flow cytometry reimbursement in 2017.
$244.1
$260.0$17.7 $4.0 ($1.8) ($4.0)
$160
$180
$200
$220
$240
$260
$280
2016 Clinical Growth Pharma Growth Flow Cuts Integ. Distractions 2017
21. Confidential 21
2017 Adjusted EBITDA Bridge (1)
• NEO expects to realize $20-30 MM of total synergies in the first 3 years after the Clarient acquisition with approximately
75% of such synergies being cost synergies as a result of efficiencies gained through the combination with Clarient.
• 2017 Adjusted EBITDA assumes $8 mm of cost synergies are realized, which are partially offset by the impact of the
integrations distractions and flow cytometry reimbursement reductions (each at 90% of the revenue impact).
(1) Based on guidance issued 4/26/17 ($, MMs)
We estimate Adj. EBITDA of $39 – $46 million in 2017
21
$34.7
$42.5
$5.0
$8.0 ($1.6) ($3.6)
$0
$10
$20
$30
$40
$50
$60
2016 Growth Synergies Flow Cuts All Other 2017
22. 22
2020 Goals
By providing uncompromising quality, exceptional service &
innovative solutions, we will be the world’s leading cancer
testing and information company!
15%+
Clinical
Volume
CAGR
20%+
Pharma
Services
Revenue
CAGR
20-25%
Adjusted
EBITDA
Margins
24. 24
NeoGenomics – At a Glance
• # 1 or 2 largest somatic cancer testing Lab in America
• Most advanced and comprehensive cancer testing menu in U.S.
• Approximately 650,000 tests will be performed in 2017
• 160,000 s.f. of space, 1,000+ employees, and > 50 M.D.s & PhDs
• Outstanding franchise with Hospitals/Pathologists
• Leader in Immuno-Oncology testing with Pharma & clinical clients
25. CMS Reimbursement is Stable in 2017
CPT Proc
Code Procedure Description
National
Unadj Rate
2014
National
Unadj
Rate
2015
National
Unadj
Rate
2016
2016 vs
2015 %
change
Final Rule -
Implied
National
Unadj Rate
2017 (1)
% Change
2017 Final
Rule vs
Prelim Rule
% Change
2017 Final
Rule vs
2016
88184 FLOW 1ST MARKER 87.77$ 94.51$ 76.26$ -19.3% 61.73$ 0.3% -19.1%
88185 FLOW EACH ADDL MARKER 53.73$ 57.49$ 46.55$ -19.0% 37.68$ 0.3% -19.1%
88189 FLOW INTERP 16 OR MORE MARKERS 110.69$ 113.91$ 114.22$ 0.3% 92.59$ 0.3% -18.9%
88374 FISH AUTOMATED PER PROBE (Multiplex Probe Stain) 255.77$ 205.54$ 345.87$ 68.3% 343.45$ 1.3% -0.7%
88374-TC FISH AUTOMATED PER PROBE TECH (Multiplex Probe Stai 193.08$ 160.26$ 299.68$ 87.0% 297.16$ 1.4% -0.8%
88374-26 FISH AUTOMATED PER PROBE INTERP (Multiplex Probe St 62.69$ 45.28$ 46.19$ 2.0% 46.30$ 0.3% 0.2%
88121 FISH AUTOMATED - UROVYSION 508.30$ 556.97$ 558.55$ 0.3% 553.76$ 1.3% -0.9%
88121-TC FISH AUTOMATED - UROVYSION 459.99$ 505.23$ 506.63$ 0.3% 501.72$ 1.4% -1.0%
88121-26 FISH AUTOMATED - UROVYSION 48.31$ 51.74$ 51.92$ 0.3% 52.04$ 0.3% 0.2%
Uses G0461 in 2014
88342 IMMUNOHISTOCHEMISTRY (1st Stain) 88.48$ 90.91$ 107.41$ 18.1% 108.38$ 0.7% 0.9%
88342 - TC IMMUNOHISTOCHEMISTRY TECH (1st Stain) 57.67$ 54.26$ 70.18$ 29.3% 71.06$ 0.8% 1.3%
88342 - PC IMMUNOHISTOCHEMISTRY INTERP (1st Stain) 30.81$ 36.65$ 37.24$ 1.6% 37.32$ 0.3% 0.2%
Uses G0462 in 2014
88341 IMMUNOHISTOCHEMISTRY (Add'l Stain) 68.42$ 67.91$ 90.23$ 32.9% 92.23$ 2.3% 2.2%
88341 - TC IMMUNOHISTOCHEMISTRY TECH (Add'l Stain) 55.88$ 45.99$ 62.30$ 35.5% 62.45$ 0.9% 0.2%
88341 - PC IMMUNOHISTOCHEMISTRY INTERP (Add'l Stain) 12.54$ 21.92$ 27.93$ 27.4% 29.79$ 5.4% 6.7%
Uses G0461 in 2014
88344 IMMUNOHISTOCHEMISTRY (each Multiplex Stain) 88.48$ 117.50$ 174.01$ 48.1% 174.78$ 0.9% 0.4%
88344 - TC IMMUNOHISTOCHEMISTRY TECH (each Multiplex Stain) 57.67$ 77.26$ 133.19$ 72.4% 133.86$ 1.1% 0.5%
88344 - PC IMMUNOHISTOCHEMISTRY INTERP (each Multiplex Stain) 30.81$ 40.25$ 40.82$ 1.4% 40.91$ 0.3% 0.2%
88361 MORPHOLOGY, EACH ANTIBODY - AUTOMATED 157.98$ 170.32$ 149.66$ -12.1% 156.83$ 0.5% 4.8%
88361-TC MORPHOLOGY TECH, EACH ANTIBODY - AUTOMATED 98.51$ 109.96$ 88.79$ -19.3% 95.82$ 1.1% 7.9%
88361-26 MORPHOLOGY INTERP, EA ANTIBODY - AUTOMATED 59.47$ 60.37$ 60.87$ 0.8% 61.01$ -0.3% 0.2%
(1) Source: CMS Final Rule on 2017 Physician Fee Schedule (CMS-1654-F issued 11/2/16). Assumes no other Physician Fee Schedule rule changes or limited coverage determinations
are implemented for 2017. Uses Estimated Conversion Factor of 35.8887 taken from Section VI(C)(1) of CMS-1654-F (page 1326 of display copy of rule on CMS website).
25
26. Confidential
Impact of Clarient Acquisition
26
Key Benefits
Outstanding Customer Mix
Similar Product Lines (1)
Synergy potential of $20mm-$30mm within 3 years
East Coast/West Coast Labs w/similar instrumentation
Combine Irvine Lab into 78,000 sq. ft. Aliso Viejo Lab
Strategic leadership in Heme cancers and Solid tumors
Significant Pharma Services opportunities
IHC
42%
FISH/ISH
19%
FLOW
14%
Molecular
15%
Cyto
5%
Other
5%
(1) Clinical operations only. Percentage of tests Performed.
SIMILAR CLINICAL
CUSTOMERS
(About 2,400)
New BIOPHARMA
CUSTOMERS
(200 Projects with
>30 Customers)
26
The Deal – Closed on 12/30/15
Approx. $292 million purchase price --- $80mm cash, 15mm
shares of NEO, $110mm Pfd. Stock
Clarient 2015 revenue $125mm and $9mm Adj EBITDA
$55 mm of Pfd Stock Redeemed at 9.1% discount in Dec 16
Bank debt refinanced in Dec 16 at favorable rates (L+350)
GE currently holds 15mm NEO shares plus $45mm Pfd Stock
27. 2017 Guidance*
• Revenue: $255 - 265 MM
• Adjusted EBITDA* 39 - 46 MM
• Adjusted Net Income* 15 - 18 MM
• Adjusted Diluted EPS* $0.17 - 0.21
* See Appendix for definitions of Adjusted EBITDA, Adjusted Net Income and Adjusted Diluted EPS as well as a reconciliation of GAAP
Net Income to Adj. EBITDA, Adj. Net Income and Adj. Diluted EPS. NeoGenomics believes that Adjusted EBITDA, Adjusted Net Income
and Adjusted Diluted EPS provide a more consistent measurement of operating performance and trends across reporting periods by
excluding from income those cash and non-cash items of expense (income) not directly related to ongoing operations. Adjusted figures
also assists investors in performing analysis that is consistent with financial models developed by research analysts. Investors should
consider non-GAAP results together with GAAP results in analyzing NeoGenomics financial performance.
2017 net income available to common stockholders calculated in accordance with GAAP will be impacted by certain non-cash charges,
including: (i) expenses related to variable stock-based compensation, (ii) approximately $7.3 million of expense related to the
amortization of customers lists and other intangibles from the Clarient acquisition, (iii) approximately $3.8 million of deemed preferred
stock dividends, and (iv) approximately $6.7 million of the amortization of the beneficial conversion feature related to the preferred stock
issued in connection with the Clarient acquisition. These non-cash charges have been included in GAAP net income (loss) available to
common shareholders and GAAP net income (loss) per share; however, they have been removed from Adjusted Net Income and Adjusted
Diluted Net Income per Share. As a result, the Company expects 2017 diluted net loss per share calculated in accordance with GAAP to
be $0.26 - $0.28 per share lower than 2017 Adjusted Diluted Net Income per Share.
27
28. Confidential
Reconciliation of GAAP Net Income to Adjusted EBITDA
Use of non-GAAP Financial Measures: NeoGenomics believes that using non-GAAP financial measures provides useful
supplemental information to investors and facilitates the analysis of the company’s core operating results and the comparison of
core operating results more consistently across reporting periods. Management also uses non-GAAP financial measures for financial
and operational decision making, planning and forecasting purposes and to manage the company’s business. These non-GAAP
financial measures enable investors to evaluate our operating results and future prospects in the same manner as management and
research analysts. The non-GAAP financial measures do not replace the presentation of GAAP financial results and should only be
used as a supplement to and not as a substitute for financial results presented in accordance with GAAP. There are limitations
inherent in non-GAAP financial measures because they exclude charges and credits that are required to be included in a GAAP
presentation, and do not therefore present the full measure of NeoGenomics recorded costs against its net revenue. In addition,
non-GAAP financial measures as defined by NeoGenomics may differ from non-GAAP measures used by other companies.
28
Reconciliation of GAAP Net Income to Non-GAAP EBITDA and Adjusted EBITDA
(Unaudited, in thousands)
For the Three-Months
Ended March 31,
2017 2016
Net Income (Loss) (per GAAP) $ (654) $ 155
Adjustments to Net Income (Loss):
Interest expense 1,364 1,593
Amortization of intangibles 1,725 2,026
Income tax expense (benefit) (825) 174
Depreciation 3,979 3,585
EBITDA $ 5,589 $ 7,533
Further adjustments to EBITDA:
Non-cash stock based compensation 1,130 703
Facility moving expenses 351 -
Adjusted EBITDA (non-GAAP) $ 7,070 $ 8,236
29. Confidential
Reconciliation of GAAP Net Income to Adjusted Net
Income & GAAP Diluted EPS to Adjusted Diluted EPS
29
Reconciliation of GAAP Net Income Available to Common Stockholders to Non-GAAP Adjusted Net
Income and GAAP Earnings per Share to Non-GAAP Adjusted Earnings per Share
(Unaudited, in thousands)
For the Three-Months
Ended March 31,
2017 2016
Net loss available to common shareholders (GAAP) $ (3,220) $ (5,412)
Adjustments to Net Loss:
Amortization of intangibles 1,725 2,026
Non-cash stock-based compensation expenses 1,130 703
Deemed dividends/ PIK dividends on preferred stock 894 1,840
Facility moving expenses 351 -
Amortization of preferred stock beneficial conversion feature 1,672 3,727
Adjusted net income (non-GAAP) $ 2,552 $ 2,884
Net loss per common share (GAAP)
Diluted EPS $ (0.04) $ (0.07)
Adjustments to diluted loss per share:
Amortization of intangibles 0.02 0.02
Non-cash stock-based compensation expenses 0.01 0.01
Deemed dividends/ PIK dividends on preferred stock 0.01 0.02
Facility moving expenses - -
Amortization of preferred stock beneficial conversion feature 0.02 0.04
Impact of including preferred shares and stock options/warrants in Adj.
Diluted Shares (3)
0.01 0.01
Adjusted Diluted EPS (non-GAAP) 0.03 0.03
30. Confidential
“Adjusted EBITDA” is defined by NeoGenomics as net income from continuing operations before: (i) interest expense, (ii) tax expense,
(iii) depreciation and amortization expense, (iv) non-cash, stock-based compensation expense, and if applicable in a reporting period
(v) acquisition related transaction expenses and other significant non-recurring or non-operating (income) or expenses.
“Adjusted Net Income” is defined by NeoGenomics as net income available to common shareholders from continuing operations plus:
(i) non-cash amortization of customer lists and other intangible assets, (ii) non-cash, stock-based compensation expense, (iii) non-cash
deemed dividends on preferred stock, (iv) non-cash amortization of preferred stock beneficial conversion feature, and if applicable in a
reporting period (v) acquisition related transaction expenses and other significant non-recurring or non-operating (income) or
expenses.
“Adjusted Diluted EPS” is defined by NeoGenomics as Adjusted Net Income divided by Adjusted Diluted Shares outstanding. Adjusted
Diluted Shares outstanding is the sum of Diluted shares outstanding and the weighted average number of common shares that would
be outstanding if the preferred stock were converted into common stock on the original issue date based on the number of days such
common shares would have been outstanding in the reporting period. In addition, If GAAP Net Income is negative and Adjusted Net
Income is positive, Adjusted Diluted Shares will also include any options or warrants that would be outstanding as dilutive instruments
using the treasury stock method.
Reconciliation of GAAP Net Income to Adjusted Figures
30
Weighted average shares used in computation of adjusted diluted
earnings per share:
Diluted Common Shares (GAAP) 78,650 76,068
Options & warrants not included in GAAP Diluted Shares (using
treasury stock method) 1,693 2,271
Weighted Avg. Preferred Shares (as converted) 6,600 14,667
Adjusted Diluted Shares outstanding (non-GAAP) 86,943 93,006
For the Three-Months
Ended March 31,
2017 2016